Budd-Chiari syndrome in Behcet's disease: a retrospective multicenter study

Basit Öğe Kaydı
dc.contributor.authorAkyol, Lutfi
dc.contributor.authorToz, Bahtiyar
dc.contributor.authorBayindir, Ozun
dc.contributor.authorZengin, Orhan
dc.contributor.authorCansu, DonduUskudar
dc.contributor.authorYigit, Murat
dc.contributor.authorCetin, Gozde Yildirim
dc.date.accessioned2024-02-23T13:55:56Z
dc.date.available2024-02-23T13:55:56Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjective To compare the clinical features, laboratory findings, and prognosis of Behget's disease (BD) patients with and without Budd-Chiari syndrome (BCS). Methods This multicenter retrospective study investigated 61 (M/F: 41/20) patients with BD, having coexistent BCS, and 169 (M/F:100/69) BD patients as the control group without BCS from 22 different centers of Turkey diagnosed between 1990 and 2017. Results Of the total 61 BD patients with BCS, the onset of the first symptom and the median age of diagnosis were earlier in contrast to BD patients without BCS (p = 0 .005 and p = 0 .007) . Lower extremity deep vein and inferior vena cava (IVC) thrombosis were more common in patients with BCS (all; p < 0.01) compared to the control group. Mortality was significantly higher in BD-BCS patients with IVC thrombosis than in the controls (p = 0 .004) . Since most of the cases in our cohort had chronic and silent form of BCS, mortality rate was 14.8%, which was on the lower range of mortality rate reported in literature (14-47%). While all BD-BCS patients received immunosuppressive (IS) agents, only half of them received additional anticoagulant treatments. Among IS agents, interferon treatment was more frequently used in this cohort (19%), compared to other series reported in literature (2.3%). Conclusion To our knowledge, this is the largest series of BD patients with BCS. Our patients had earlier disease onset and diagnosis, higher frequency of IVC thrombosis, and higher mortality rate, compared to BD patients without BCS. Mortality was significantly higher in BD-BCS patients with IVC thrombosis compared to controls.en_US
dc.identifier.doi10.1007/s10067-021-05878-2
dc.identifier.endpage186en_US
dc.identifier.issn0770-3198
dc.identifier.issn1434-9949
dc.identifier.issue1en_US
dc.identifier.pmid34368908en_US
dc.identifier.scopus2-s2.0-85112040681en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage177en_US
dc.identifier.urihttps://doi.org/10.1007/s10067-021-05878-2
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11029
dc.identifier.volume41en_US
dc.identifier.wosWOS:000682817700001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofClinical Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet's Diseaseen_US
dc.subjectBudd-Chiari Syndromeen_US
dc.subjectInferior Vena Cavaen_US
dc.subjectPrognosisen_US
dc.subjectThrombosisen_US
dc.titleBudd-Chiari syndrome in Behcet's disease: a retrospective multicenter studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu